NCT03204032

A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Extrapancreatic Neuroendocrine Tumor

A Phase II Randomized,Controlled,Open Label,Multicentre Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Extrapancreatic Neuroendocrine Tumor

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Chinese Academy of Medical Sciences · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: —

Summary

A Phase II Randomized,Controlled,Open Label,Multicentre Study to evaluate the efficacy and safety of Tegafur combined with Temozolomide versus Tegafur combined with Temozolomide and Thalidomide in subjects with Advanced Extrapancreatic Neuroendocrine Tumor

Conditions

• Extrapancreatic Neuroendocrine Tumor

Interventions

Type	Name	Description
DRUG	Tegafur	Tegafur 40-60mg po bid(d1-d14);
DRUG	Temozolomide	200mg po qd(d10-d14)
DRUG	Thalidomide	Thalidomide 100mg po qd(d1-d7) Thalidomide 200mg po qd(d8-d14) Thalidomide 300mg po qd(d15-d21)

Timeline

• Start date: 2016-10-01
• Primary completion: 2017-10-01
• Completion: 2018-09-01
• First posted: 2017-06-29
• Last updated: 2017-06-29

Locations

1 site across 1 country: China